PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN
Abstract Targeting mutant BRAF in patients with melanomas harboring this oncogene has been highly successful as a first-line treatment, but other mutations may affect its efficacy and alter the route of acquired resistance resulting in recurrence and poor prognosis. As an evolving strategy, melanoma...
Saved in:
Main Authors: | Yifei Qin, Qiang Zuo, Lei Huang, Liping Huang, Glenn Merlino, Yanlin Yu |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/296a03e409584af690987eefc1e8c182 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
by: Hima Patel, et al.
Published: (2021) -
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
by: Maria Gonzalez-Cao, et al.
Published: (2021) -
ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
by: Shujun Han, et al.
Published: (2018) -
Inhibition of cardiac PERK signaling promotes peripartum cardiac dysfunction
by: Takashi Shimizu, et al.
Published: (2021) -
Publisher Correction: ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
by: Shujun Han, et al.
Published: (2018)